**Buprenorphine SR-LAB Administration Instructions**

Buprenorphine SR-**LAB** is a new sustained release buprenorphine product that has been developed to provide up to 72 hours of analgesia in laboratory animals such as mice, rats, and rabbits.

* The 1 mg/ml Buprenorphine SR-**LAB** formulation will retain stability even without refrigeration. This formulation has been tested at room temperature for one year and has retained its stability and efficacy, while this is not true for the Buprenorphine SR-**HCl** formulated for other species where this formulation must be refrigerated to maintain stability and efficacy.
* Dosages:
	+ **Rats - Dose: 1.0-1.2 mg/kg**
	+ **Mice – Dose 0.5-1.0 mg/kg**
	+ **Rabbits – 0.1 mg/kg**
* Administration:
	+ Draw up the buprenorphine SR-**LAB** with an 18 g needle due to the viscosity of the drug and change to a smaller sized needle, i.e., 21-25 g, prior to administration.
	+ To reduce drug loss in the needle and syringe hub when changing needles, draw back all drug into the syringe prior to changing the needle then realign the proper volume when the new needle has been added.
	+ Administer subcutaneously on back of neck between the shoulder blades preferable while the animal is anesthetized because it can take more time than usual to administer due to the viscosity of the drug.
	+ Administer *slowly* and finish injecting before the needle is pulled out through skin.
	+ Pinch the injection site for approximately 10 seconds after removing the needle.
	+ Buprenorphine SR-**LAB** has been shown to reach therapeutic levels of analgesia in less than 1 hour in most situations for mice, rats, and rabbits, therefore, it should be administered prior to making the incision to allow for therapeutic levels to be attained prior to the animal waking from anesthesia.
* DO NOT combine the buprenorphine SR-**LAB** with any other drugs and do not attempt to dilute the formulation as this will disrupt the integrity of the polymer matrix and its sustained release delivery characteristics.
* Please note, there have been reports of skin irritation with prior formulations of Buprenorphine SR that has been rectified with the Buprenorphine SR-**LAB** formulation. Please report any adverse reactions to the DLAM technical staff.